000
| 01400nam 2200301za 4500 |
---|
001 | 9.847520 |
---|
003 | CaOODSP |
---|
005 | 20221107153448 |
---|
007 | cr ||||||||||| |
---|
008 | 171121s2018 onca o f000 0 eng d |
---|
020 | |a9780660239385|z9780660239392 |
---|
040 | |aCaOODSP|beng |
---|
043 | |an-cn--- |
---|
086 | 1 |aNR16-173/2017E-PDF |
---|
110 | 2 |aNational Research Council Canada. |
---|
245 | 10|aAMVAD adjuvant for mucosal vaccines (L-11561) |h[electronic resource]. |
---|
260 | |a[Ottawa] : |bNational Research Council Canada, |c[2018] |
---|
300 | |a[2] p. : |bill. |
---|
500 | |aIssued also in French under title: Adjuvant AMVAD pour vaccins muqueux (L-11561). |
---|
500 | |aCaption title. |
---|
500 | |a"January 2017." |
---|
520 | |a“The NRC has developed a novel archaeal polar lipid mucosal vaccine adjuvant and delivery (AMVAD) platform capable of generating mucosal and systemic immune responses against a wide range of pathogens that infect mucosal surfaces or use them to gain entry to the body”--Highlights, p. [1]. |
---|
530 | |aIssued also in print format. |
---|
693 | 4|aImmunological adjuvants |
---|
693 | 4|aLiposomes |
---|
775 | 08|tAdjuvant AMVAD pour vaccins muqueux (L-11561) |w(CaOODSP)9.847522 |
---|
776 | 0#|tAMVAD adjuvant for mucosal vaccines |w(CaOODSP)9.847521 |
---|
856 | 40|qPDF|s166 KB|uhttps://publications.gc.ca/collections/collection_2018/cnrc-nrc/NR16-173-2017-eng.pdf |
---|